These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26497923)

  • 1. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Necchi A; Pond GR; Raggi D; Giannatempo P; Vogelzang NJ; Grivas P; Galsky MD; Bellmunt J; Sonpavde G
    Clin Genitourin Cancer; 2017 Feb; 15(1):23-30.e2. PubMed ID: 27324051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
    Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
    J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
    Naiki T; Kawai N; Hashimoto Y; Okamura T; Ando R; Yasui T; Okada A; Etani T; Tozawa K; Kohri K
    Int J Clin Oncol; 2014; 19(3):516-22. PubMed ID: 23749066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequential Treatment of Advanced Squamous Lung Cancer: 
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
    Xu J; Liu X; Gao H; Guo W; Tang C; Li X; Li J; Qin H; Wang W; Qu L; Wang H; Yang H; Yang L
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):308-14. PubMed ID: 25975302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
    Takeyama Y; Kato M; Nishihara C; Yamasaki T; Iguchi T; Tamada S; Kuratsukuri K; Nakatani T
    Int J Clin Oncol; 2018 Oct; 23(5):944-950. PubMed ID: 29785621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
    Niegisch G; Fimmers R; Siener R; Park SI; Albers P;
    Eur Urol; 2011 Nov; 60(5):1087-96. PubMed ID: 21839579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.